
Sign up to save your podcasts
Or


🚨 New breakthrough in hypertension care!
💊 The Launch-HTN trial shows lorundrostat — a selective aldosterone synthase inhibitor — significantly lowers systolic BP in patients with uncontrolled or treatment-resistant hypertension.
📉 −16.9 mmHg vs −7.9 mmHg with placebo (P
🧪 Safe, well-tolerated, and effective across subgroups.
A potential game-changer in aldosterone-targeted therapy! 🔄💥 #Hypertension #Cardiology #ClinicalTrials #PrecisionMedicine
By Dr RR Baliga, MD, MBA5
66 ratings
🚨 New breakthrough in hypertension care!
💊 The Launch-HTN trial shows lorundrostat — a selective aldosterone synthase inhibitor — significantly lowers systolic BP in patients with uncontrolled or treatment-resistant hypertension.
📉 −16.9 mmHg vs −7.9 mmHg with placebo (P
🧪 Safe, well-tolerated, and effective across subgroups.
A potential game-changer in aldosterone-targeted therapy! 🔄💥 #Hypertension #Cardiology #ClinicalTrials #PrecisionMedicine

894 Listeners

3,374 Listeners

21,499 Listeners